← Library

Tirzepatide

Peptide Index
FDA ApprovedSince 2022
Also known as Mounjaro, Zepbound

Function

Primary
Type 2 Diabetes · Obesity
Mechanism
Dual GIP + GLP-1 receptor agonist — synergistic effect on insulin secretion, appetite suppression, and adiposity reduction.
Evidence
Clinical RCT (Phase III)
Research
Phase III SURPASS/SURMOUNT programs

Dosing

Range
2.5–15 mg/week
Frequency
Weekly
Route
Subcutaneous

Cycling

Continuous; 4-week titration steps from 2.5 → 15 mg.

Benefits

  • ·Superior weight loss vs GLP-1 alone (up to ~22%)
  • ·HbA1c reduction ~2.0–2.5%
  • ·Improved lipids and BP

Risks

  • ·GI side effects (nausea, vomiting, constipation)
  • ·Gallbladder disease
  • ·Hypoglycemia with sulfonylureas/insulin
  • ·Thyroid C-cell tumor warning

Contraindications

  • ·MTC / MEN-2
  • ·Pregnancy
  • ·Severe gastroparesis

Regulatory

FDA-Approved Rx

Functional Groups

Weight Loss

Cited Works

  1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503.source
  2. Jastreboff AM et al. Tirzepatide for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205.source
View full reference repository →
Sign in to save favorites & stacks